"Keytruda had sales of $483 million in the quarter and $1.4 billion over 2016, and could get U.S. approval in March for two other tumor types. Edward Jones analyst Ashtyn Evans wrote to investors that she expects annual Keytruda sales to reach $7 billion by 2020."
The correct figure is 6.5%, split 75/25 with Ono.... we get 4.9%. Considering higher Keytruda sales are cannibalizing Opdivo sales, we are out 95%. Still sounding good?
Yup still sounds great ! 4.9% for doing nothing , along with control over what keytruda can and cannot do in the future because of patent rights sounds great
The number drops to 1.9% in 2024 -2026 and zero in 2027. Patent rights and control over Keytruda disappear with this agreement. "The agreement will result in the dismissal with prejudice of all patent litigation between the companies pertaining to Keytruda." Bristol has blown leadership in the PD1L field along with immunoncolgy
Need new leaders that have knowledge of clinical science. Currently, leaders are a bunch of yes, yes, yes. No substance.
Couldn't agree more. It's all about he indications! With RCC opdivo now just bumped the earnings potential up 2bn more. All of these pd1 drugs will be making bank
Resistance development to checkpoint inhibitors was not foreseen and will become a larger challenge than expected.
7% revenue increase in the third quarter results in a nearly10% stock price decline since October 11. Hardly making bank.
Just keep delivering lunch and trying to explain why your drug is worth bankruptcy for cancer patients. Collect your big salary and go home and whine, because you aren't capable of earning an honest living.
